2.

免疫联合化疗临床研究

Clinical trials of ICI with chemotherapy

Study	Phase	Histology, PD-L1	Line	Study design	Key findings	HR (95%CI)
EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase.
KEYNOTE-189[30]	Ⅲ	Nonsquamous	First-line	Carboplatin/cisplatin+ pemetrexed/pembrolizumab	12-mon OS: 69.2% vs 49.4%	0.49 (0.38-0.64)
KEYNOTE-407[31]	Ⅲ	Squamous	First-line	Carboplatin/paclitaxel or nab-paclitaxel/pembrolizumab	mOS: 15.9 mon vs 11.3 mon	0.64 (0.49-0.85)
IMpower131[32]	Ⅲ	Squamous	First-line	Carboplatin+ nab-paclitaxel/ atezolizumab	mPFS: 6.3 mon vs 5.6 mon	0.715 (0.603-0.848)
IMpower132[33]	Ⅲ	Nonsquamous	First-line	Carboplatin/cisplatin+ pemetrexed/atezolizumab	mPFS: 7.6 mon vs 5.2 mon	0.60 (0.49-0.73)
IMpower150[34]	Ⅲ	Nonsquamous, including EGFR/ALK+	First-line	Carboplatin/paclitaxel+ bevacizumab/atezolizumab	mOS: 19.2 mon vs 14.7 mon	0.78 (0.64-0.96)